Table 2 Summary of AEs by treatment group according to MedDRA system

From: Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial

MedDRA system organ class (preferred term)

BMAC (N = 107)

SVF (N = 109)

UCT (N = 116)

CSI (N = 108)

All subjects (N = 440)

 

n (%)

95% CI

n (%)

95% CI

n (%)

95% CI

n (%)

95% CI

n (%)

95% CI

Musculoskeletal connective tissue disorders

          

 Arthralgia

27 (25.2)

17.3, 34.6

25 (22.9)

15.4, 32.0

30 (25.9)

18.2, 34.8

28 (25.9)

18.0, 35.2

110 (25.0)

21.0, 29.3

 Joint stiffness

13 (12.1)

6.6, 19.9

6 (5.5)

2.0, 11.6

8 (6.9)

3.0, 13.1

8 (7.4)

3.3, 14.1

35 (8.0)

5.6, 10.9

 Joint swelling

19 (17.8)

11.0, 26.3

16 (14.7)

8.6, 22.7

28 (24.1)

16.7, 33.0

8 (7.4)

3.3, 14.1

71 (16.1)

12.8, 19.9

  1. The safety population is defined as the 440 subjects who received study treatment. The AEs are those with an incidence of at least 5%. MedDRA denotes Medical Dictionary for Regulatory Activities, version 21.1.
  2. 95% CIs that do not overlap are statistically significant.